Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine
Meningococcal Antigen Typing System (MATS) is the combination of a sandwich ELISA (Enzyme Linked Immunosorbent Assay) developed to estimate the level of expression and immunoreactivity of the antigen components (fHbp, NHBA, and NadA) of the 4CMenB vaccine (Bexsero, GSK Vaccines) in circulating, serogroup B meningococcal (MenB) strains, with the molecular typing of PorA, the main antigenic component in the outer membrane vesicles (OMV). MATS has been proven to be a good surrogate of the accepted correlate of protection for meningococcus (hSBA), thus providing a quick, conservative and reproducible method to assess vaccine coverage. The method has been successfully transferred and standardized in several public health laboratories across Europe, North America, and Australia and used to screen thousands of isolates all over the world. Here we describe the sandwich ELISA method applied to assess the expression and cross-reactivity of fHbp, NHBA, and NadA in MenB isolates.
Key wordsVaccine Neisseria meningitidis Antibodies Coverage Meningococcal Antigen Typing System (MATS) ELISA Serum Bactericidal Assay (SBA)
Acknowledgments, Sponsorship, and Conflict of Interest
Material and support for this study were provided by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in analysis and interpretation of data. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of the manuscript for factual accuracy, but we are solely responsible for final content and interpretation. We received no financial support or other form of compensation related to the development of the manuscript.
G.B., B.B., E.M., C.G., M.A., and M.M.G. are currently employed by the GSK group of companies.
G.B., B.B., E.M., C.G., M.A., and M.M.G. participated in the drafting and revision of the manuscript.
This is a methodology description, no data are included in this publication.
This work was sponsored by Novartis Vaccines and Diagnostics Srl; in March 2015 the Novartis non-influenza Vaccines business was acquired by the GSK group of companies. The sponsor was involved in all stages of the study conduct and analysis.